{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:20:55Z","timestamp":1781889655403,"version":"3.54.5"},"reference-count":66,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T00:00:00Z","timestamp":1508198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Integr Cancer Ther"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:p>Introduction: Conventional cancer treatment, including surgery, chemotherapy, and radiotherapy, may not be sufficient to eradicate all malignant cells and prevent recurrence. Intensive treatment often leads to a depressed immune system, drug resistance, and toxicity, hampering the treatment outcomes. BioBran\/MGN-3 Arabinoxylan is a standardized arabinoxylan concentrate which has been proposed as a plant-based immunomodulator that can restore the tumor-induced disturbance of the natural immune system, including natural killer cell activity to fight cancer, complementing conventional therapies. Objectives: To comprehensively review the available evidence on the effects and efficacies of MGN-3 as a complementary therapy for conventional cancer treatment. Methods: Systematic search of journal databases and gray literature for primary studies reporting the effects of MGN-3 on cancer and cancer treatment. Results: Thirty full-text articles and 2 conference abstracts were included in this review. MGN-3 has been shown to possess immunomodulating anticancer effects and can work synergistically with chemotherapeutic agents, in vitro. In murine models, MGN-3 has been shown to act against carcinogenic agents, and inhibit tumor growth, either by itself or in combination with other anticancer compounds. Fourteen successful MGN-3 treated clinical cases were found. Eleven clinical studies, including 5 nonrandomized, pre-post intervention studies and 6 randomized controlled trials (RCTs) were located. Reported effects include enhanced immunoprofile, reduced side effects, improved treatment outcomes; one RCT established significantly increased survival rates. There are no reports on adverse events on MGN-3. Most of the clinical trials are small studies with short duration. Conclusion: There is sufficient evidence suggesting MGN-3 to be an effective immunomodulator that can complement conventional cancer treatment. However, more well-designed RCTs on MGN-3 are needed to strengthen the evidence base.<\/jats:p>","DOI":"10.1177\/1534735417735379","type":"journal-article","created":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T04:34:16Z","timestamp":1508214856000},"page":"165-178","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":45,"title":["Evidence-Based Review of BioBran\/MGN-3 Arabinoxylan Compound as a Complementary Therapy for Conventional Cancer Treatment"],"prefix":"10.1177","volume":"17","author":[{"given":"Soo Liang","family":"Ooi","sequence":"first","affiliation":[{"name":"Centre of Complementary & Alternative Medicine, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"McMullen","sequence":"additional","affiliation":[{"name":"Charles Sturt University, Bathurst, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Golombick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipl","family":"Nut","sequence":"additional","affiliation":[{"name":"St George Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sok Cheon","family":"Pak","sequence":"additional","affiliation":[{"name":"Charles Sturt University, Bathurst, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,10,17]]},"reference":[{"key":"bibr1-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-15-0578"},{"key":"bibr2-1534735417735379","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4236\/jct.2010.11001","volume":"1","author":"Sudhakar A","year":"2010","journal-title":"J Cancer Sci Ther"},{"key":"bibr3-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-016-1393-4"},{"key":"bibr4-1534735417735379","first-page":"2229","volume":"32","author":"Kuroki M","year":"2012","journal-title":"Anticancer Res"},{"key":"bibr5-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.03.026"},{"key":"bibr6-1534735417735379","first-page":"183","volume":"10","author":"Biemar F","year":"2013","journal-title":"Cancer Biol Med"},{"key":"bibr7-1534735417735379","unstructured":"BioBran.org. Biobran MGN-3\u2014an overview. https:\/\/biobran.org\/overview. Accessed May 18, 2017."},{"key":"bibr8-1534735417735379","first-page":"14","volume-title":"BioBran\/MGN-3 (Rice Bran Arabinoxylan Coumpound): Basic and Clinical Application to Integrative Medicine","volume":"2013","author":"Miura T","edition":"2"},{"key":"bibr9-1534735417735379","unstructured":"Paterson A. Therapeutic properties of biobran MGN-3. http:\/\/www.positivehealth.com\/article\/nutraceuticals\/therapeutic-properties-of-biobran-mgn-3. Posit Heal. Published September 2002. Accessed September 19, 2017."},{"key":"bibr10-1534735417735379","volume-title":"BioBran\/MGN-3 (Rice Bran Arabinoxylan Compound): Basic and Clinical Application to Integrative Medicine","author":"Tazawa K","year":"2013","edition":"2"},{"key":"bibr11-1534735417735379","first-page":"3541S","volume":"134","author":"Ghoneum M","year":"2004","journal-title":"J Nutr"},{"key":"bibr12-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2007.03.511"},{"key":"bibr13-1534735417735379","first-page":"S117","volume":"96","author":"Cholujova D","year":"2011","journal-title":"Haematologica"},{"key":"bibr14-1534735417735379","volume":"74","author":"Badr El-Din NK","year":"2014","journal-title":"Cancer Res"},{"key":"bibr15-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2015-5312"},{"key":"bibr16-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1080\/19390210802329196"},{"key":"bibr17-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrs119"},{"key":"bibr18-1534735417735379","first-page":"314","volume":"24","author":"Ghoneum M","year":"2000","journal-title":"Cancer Detect Prev"},{"key":"bibr19-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1177\/039463201402700408"},{"key":"bibr20-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1177\/039463201102400412"},{"key":"bibr21-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1211\/0022357044922"},{"key":"bibr22-1534735417735379","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2009_02_89"},{"key":"bibr23-1534735417735379","first-page":"56","volume":"1","author":"Hajt\u00f3 T","year":"2013","journal-title":"Adv Med Plant Res"},{"key":"bibr24-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9017902"},{"key":"bibr25-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1080\/10408398.2012.705188"},{"key":"bibr26-1534735417735379","first-page":"46","volume":"1","author":"Meshitsuka K","year":"2016","journal-title":"Pers Med Universe (Japanese Ed.)"},{"key":"bibr27-1534735417735379","volume-title":"Paper presented at the 8th International Congress on Anti-Aging & Biomedical Technologies;","author":"Ghoneum M"},{"key":"bibr28-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(03)00458-0"},{"key":"bibr29-1534735417735379","first-page":"859","volume":"25","author":"Ghoneum M","year":"2005","journal-title":"Anticancer Res"},{"key":"bibr30-1534735417735379","first-page":"4187","volume":"25","author":"Ghoneum M","year":"2005","journal-title":"Anticancer Res"},{"key":"bibr31-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1016\/j.cdp.2008.02.006"},{"key":"bibr32-1534735417735379","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2011_02_118"},{"key":"bibr33-1534735417735379","first-page":"81","volume":"34","author":"Ghoneum M","year":"2014","journal-title":"Anticancer Res"},{"key":"bibr34-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2014.11.001"},{"key":"bibr35-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1300\/J133v03n04_02"},{"key":"bibr36-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0773.2003.920608.x"},{"key":"bibr37-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1080\/01635580701627285"},{"key":"bibr38-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.04.012"},{"key":"bibr39-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1177\/1534735416642287"},{"key":"bibr40-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2016.1192204"},{"key":"bibr41-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2016-5259"},{"key":"bibr42-1534735417735379","first-page":"281","volume":"14","author":"Kawai T","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"bibr43-1534735417735379","first-page":"273","volume":"14","author":"Kaketani K","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"bibr44-1534735417735379","first-page":"289","volume":"14","author":"Okamura Y","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"bibr45-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1097\/00042728-200601000-00031"},{"key":"bibr46-1534735417735379","doi-asserted-by":"publisher","DOI":"10.15761\/CCRR.1000176"},{"key":"bibr47-1534735417735379","doi-asserted-by":"publisher","DOI":"10.15761\/CCRR.1000244"},{"key":"bibr48-1534735417735379","first-page":"217","volume-title":"Anti-Aging Medical Therapeutics","author":"Ghoneum M","year":"1999"},{"key":"bibr49-1534735417735379","first-page":"267","volume":"14","author":"Takahara K","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"bibr50-1534735417735379","first-page":"295","volume":"14","author":"Tsunekawa H","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"bibr51-1534735417735379","first-page":"1011","volume":"6","author":"Lissoni P","year":"2008","journal-title":"Cancer Ther"},{"key":"bibr52-1534735417735379","first-page":"5145","volume":"30","author":"Bang MH","year":"2010","journal-title":"Anticancer Res"},{"key":"bibr53-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1344-z"},{"key":"bibr54-1534735417735379","first-page":"13","volume":"20","author":"Masood AI","year":"2013","journal-title":"Prof Med J"},{"key":"bibr55-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/974390"},{"key":"bibr56-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1016\/j.eujim.2016.10.004"},{"key":"bibr57-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1177\/1534735416635742"},{"key":"bibr58-1534735417735379","doi-asserted-by":"publisher","DOI":"10.4172\/2376-0281.1000205"},{"key":"bibr59-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"bibr60-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03535.x"},{"key":"bibr61-1534735417735379","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3965"},{"key":"bibr62-1534735417735379","doi-asserted-by":"publisher","DOI":"10.5045\/br.2014.49.3.162"},{"key":"bibr63-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.67"},{"key":"bibr64-1534735417735379","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0000000000000243"},{"issue":"2","key":"bibr65-1534735417735379","volume":"1","author":"Ghoneum M","year":"2016","journal-title":"Austin Immunol"},{"key":"bibr66-1534735417735379","unstructured":"The safety of Biobran\/MGN-3. In: BioBran\/MGN-3 (Rice Bran Arabinoxylan Coumpound): Basic and Clinical Application to Integrative Medicine. 2nd ed. Tokyo, Japan: BioBran Research Foundation; 2013:9-13."}],"container-title":["Integrative Cancer Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1534735417735379","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1534735417735379","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1534735417735379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:18:48Z","timestamp":1777454328000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1534735417735379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,17]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1177\/1534735417735379"],"URL":"https:\/\/doi.org\/10.1177\/1534735417735379","relation":{},"ISSN":["1534-7354","1552-695X"],"issn-type":[{"value":"1534-7354","type":"print"},{"value":"1552-695X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,17]]}}}